Phio Pharmaceuticals (PHIO) Tax Provisions (2017 - 2025)
Phio Pharmaceuticals' (PHIO) quarterly Tax Provisions came in at $2.6 million in Q4 2025, up 675.37% on a YoY basis from $337000.0 in Q4 2024, and up 675.37% quarter-over-quarter from $337000.0 in Q4 2024.
Powered by 
Analysis
Phio Pharmaceuticals (PHIO) Tax Provisions (2017 - 2025) Analysis & Trends
Phio Pharmaceuticals (PHIO) has reported Tax Provisions for 3 consecutive years, with $2.6 million the latest figure, recorded in Q4 2025.
- For the quarter ending Q4 2025, Tax Provisions rose 675.37% year-over-year to $2.6 million; the trailing twelve-month figure through Dec 2025 stood at $2.6 million (up 675.37% YoY), and the FY2025 full-year result was $2.6 million, up 675.37% from the prior year.
- Tax Provisions improved to $2.6 million in Q4 2025 per PHIO's latest filing, from $337000.0 in the prior quarter.
- Across five years, Tax Provisions topped out at $2.6 million in Q4 2025 and bottomed at $337000.0 in Q4 2024.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Taxes (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 211.73 Bn | 197.74 Bn | 7.24 Bn | 393.00 Mn |
| 2 | Gilead Sciences | 180.92 Bn | 177.74 Bn | 6.22 Bn | 242.00 Mn |
| 3 | Vertex Pharmaceuticals | 132.16 Bn | 124.30 Bn | 2.84 Bn | 292.00 Mn |
| 4 | Regeneron Pharmaceuticals | 82.89 Bn | 74.90 Bn | 3.93 Bn | 230.90 Mn |
| 5 | Argenx Se | 61.41 Bn | 56.23 Bn | 1.37 Bn | -59.00 Mn |
| 6 | Moderna | 53.99 Bn | 48.85 Bn | 52.00 Mn | 15.00 Mn |
| 7 | Alnylam Pharmaceuticals | 34.48 Bn | 31.18 Bn | 992.69 Mn | 13.31 Mn |
| 8 | Biogen | 31.15 Bn | 29.86 Bn | 1.96 Bn | 34.90 Mn |
| 9 | Roivant Sciences | 30.05 Bn | 30.05 Bn | 1.16 Mn | -3.96 Mn |
| 10 | Phio Pharmaceuticals | 12.08 Mn | 12.08 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2025 | 2.61 Mn |
| Dec 31, 2024 | 337,000.00 |
| Mar 31, 2017 | -1.62 Mn |